Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $552.56, for a total transaction of $4,586,248.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $24,960,240.32. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Performance

UTHR traded up $8.76 during trading on Thursday, reaching $555.91. The stock had a trading volume of 531,986 shares, compared to its average volume of 498,740. The business has a 50-day moving average of $559.06 and a 200-day moving average of $527.20. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The stock has a market cap of $23.60 billion, a PE ratio of 20.52, a PEG ratio of 1.78 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the firm earned $6.63 EPS. Equities research analysts forecast that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Arjuna Capital lifted its position in United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 18 shares during the last quarter. Sage Rhino Capital LLC grew its holdings in shares of United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC grew its holdings in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 24 shares during the last quarter. Meeder Advisory Services Inc. increased its stake in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after buying an additional 26 shares during the period. Finally, Independent Advisor Alliance increased its stake in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

UTHR has been the subject of several research reports. UBS Group upped their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Bank of America boosted their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research note on Thursday, May 7th. Finally, Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.